Clinical Trial Update: A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating sequential ONCOS-102 plus pembrolizumab in advanced or unresectable melanoma progressing after PD-1 blockade.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ONCOS-102
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Targovax Oy | Conditions: Advanced or Unresectable Melanoma Progressing After PD1 Blockade | Phase 1 | Status: COMPLETED | Results posted: 2021-08-09